Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 10:13 AM ET

InspireMD, Inc.

Corporation · organized in Delaware · formed more than five years before filing · Miami, FL · formerly Saguaro Resources, Inc.

$42.2Mreported sold (max)

24investors (max)

19offerings

19Form D filings

2011–2025filing years

0new, last 12 mo

Follow this issuer Connect me with this sponsor Email me the full report Look further ↓

Data last updated Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer Aug 4, 2025 · Courts (RECAP) last checked: Oct 24, 2026, 2:12 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

InspireMD, Inc. is a corporation organized in Delaware (formed more than five years before filing), based in Miami, FL.

What this means A deal company is usually set up for one investment; its Form D is the notice it files after selling to investors.

It has filed 19 Form D filings (19 originals, 0 amendments) for 19 offerings between Apr 2011 and Aug 2025. The latest filing of each offering reports a combined $117.3M sold of an indefinite amount offered to 102 investors; industry as reported: industry reported as "Other", biotechnology, other health care; latest exemption Rule 506(b).

What this means A repeat filer — 19 separate raises over about 14 years. Amendments are routine updates (an ongoing raise must update its Form D at least once a year).

Key people as listed: Andrea Tommasoli (executive officer), Gary Roubin, M.D. (director), Kathryn Arnold (director), Marvin Slosman (executive officer and director), Michael Berman (director) and 25 more.

What this means These are the people the company itself named as running or promoting it. Tap a name to see every other deal they are on.

Reported money out: $7.48M in sales commissions (latest filing per offering). Paid to sell it: A.G.P./Alliance Global Partners, BofA Securities, Inc., Dawson James Securities, Inc., JMP SECURITIES LLC and 4 more.

What this means $7.48M went to brokers for selling it (about 6.4% of what was sold).

Activity: 0 new offerings in the last 12 months; no amendment on file; latest filing Aug 4, 2025.

What this means No new raise filed in the past year — this deal company may be done raising, or simply quiet.

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched InspireMD, Inc..

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY), property records (NYC, FL, IL and TX counties) — 2 court cases matching the name listed in Key records below.

What this means 2 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 19 public filings for InspireMD, Inc. and found 15 differences, 1 worth asking the sponsor about: 9 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

Business registration (state registry / Secretary of State)

Delaware (state of organization): registry has not been searched (Delaware publishes no bulk file).
Florida (business-address state): registry searched (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026) — no registration found under this name.

State business registry (Secretary of State) 0 records matched to InspireMD, Inc.

No Secretary of State record matched in the registries searched (the issuer's reported state of incorporation, DE, has not been searched). Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

2 possible matches are in human review and not shown.

What the community is saying

Community search for InspireMD, Inc. has not run yet — it is joining a line of 49,456 names; searches run around the clock at the hosts' allowed rate. Searched so far: 641 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

2 cases: 1 dismissed, 1 judgment

Medpace, Inc. v. InspireMD, Inc. dismissed

District Court, S.D. Ohio · No. 1:16-cv-00830 · Filed Aug 10, 2016 · Closed Apr 25, 2019 · Nature of suit: 190 Contract: Other · Cause: 28:1332 Diversity-Breach of Contract

Role of InspireMD, Inc.: Defendant · Outcome: Terminated 2019-04-25 — FJC Integrated Database disposition: Voluntarily dismissed Docket on CourtListener ↗

exact company name; name has one distinctive word; court in OH (not the issuer's state)

Microbanc, LLC v. InspireMD, Inc. judgment

District Court, S.D. New York · No. 1:16-cv-03860 · Filed May 24, 2016 · Closed Jan 23, 2018 · Nature of suit: 190 Contract: Other · Cause: 28:1446bc Notice of Removal - Breach of Contract

Role of InspireMD, Inc.: Defendant · Outcome: Terminated 2018-01-23 — FJC Integrated Database disposition: Judgment on motion before trial; judgment for defendant Docket on CourtListener ↗

exact company name; name has one distinctive word; court in NY (not the issuer's state)

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:12 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched InspireMD, Inc...

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

None found in sources searched — federal bankruptcy courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:12 AM ET.

4. Differences between public sources

No comparisons published

What is compared

No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.

15 differences found between the filings for InspireMD, Inc. — 1 worth asking about (compared 19 filings on Oct 24, 2026)

Note · Sep 25, 2012 – May 31, 2013

Bankruptcy case: Nathaniel Thomas and Verta Vanessa Thomas — filed Sep 25, 2012

United States Bankruptcy Court, M.D. Florida docket "Nathaniel Thomas and Verta Vanessa Thomas" filed Sep 25, 2012, closed May 31, 2013. Patrick Verta (listed on the same filings) is listed as Debtor ("Nathaniel Thomas and Verta Vanessa Thomas"). Our match estimate: 70%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Docket · United States Bankruptcy Court, M.D. Florida ↗Patrick Verta — PartnerFacts page ↗

Sources

Worth asking · Mar 31, 2011 – May 30, 2023

9 Form Ds were filed more than 15 days after the first sale

Form D filed 61 days after the first sale — InspireMD, Inc. · Form D filed 130 days after the first sale — InspireMD, Inc. · Form D filed 148 days after the first sale — InspireMD, Inc. · Form D filed 148 days after the first sale — InspireMD, Inc. · Form D filed 148 days after the first sale — InspireMD, Inc. · and 4 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Oct 1, 2012 ↗InspireMD, Inc. — PartnerFacts page ↗Form D · Aug 26, 2011 ↗Form D · Aug 26, 2011 ↗

Sources

Form D · Oct 1, 2012 ↗ (Oct 1, 2012)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)
Form D · Aug 26, 2011 ↗ (Aug 26, 2011)
Form D · Aug 26, 2011 ↗ (Aug 26, 2011)
Form D · Aug 26, 2011 ↗ (Aug 26, 2011)
Form D · Aug 26, 2011 ↗ (Aug 26, 2011)
Form D · Aug 26, 2011 ↗ (Aug 26, 2011)
Form D · May 30, 2023 ↗ (May 30, 2023)

Note · Aug 1, 2012 – Oct 1, 2012

No amendment in the last 12 months on an offering that may still be open — InspireMD, Inc. (latest filing Oct 1, 2012)

The latest filing for this offering is dated Oct 1, 2012 (first sale Aug 1, 2012). It reports $0 sold of an indefinite amount offered. No later amendment is in our index as of Oct 24, 2026.

What this means SEC rules expect a yearly amendment while an offering is still going. The raise may simply have ended — a Form D does not say when it closed. Ask the sponsor whether the offering closed, when, and at what amount.

Form D · Oct 1, 2012 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Oct 1, 2012 ↗ (Oct 1, 2012)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Apr 18, 2011 – Apr 27, 2011

No amendment in the last 12 months on an offering that may still be open — InspireMD, Inc. (latest filing Apr 27, 2011)

The latest filing for this offering is dated Apr 27, 2011 (first sale Apr 18, 2011). It reports $425,000 sold of $10,000,000 offered. No later amendment is in our index as of Oct 24, 2026.

Form D · Apr 27, 2011 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Apr 27, 2011 ↗ (Apr 27, 2011)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Jan 18, 2013 – Mar 28, 2016

James Barry's role changed at InspireMD, Inc.: director → executive officer, director

The Jan 18, 2013 filing lists James Barry as director; the Mar 28, 2016 Form D lists executive officer, director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Jan 18, 2013 ↗Form D · Mar 28, 2016 ↗James Barry — PartnerFacts page ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Jan 18, 2013 ↗ (Jan 18, 2013)
Form D · Mar 28, 2016 ↗ (Mar 28, 2016)
James Barry — PartnerFacts page ↗
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Nov 2, 2012 – Jan 18, 2013

Ofir Paz's role changed at InspireMD, Inc.: executive officer, director → director

The Nov 2, 2012 filing lists Ofir Paz as executive officer, director; the Jan 18, 2013 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Nov 2, 2012 ↗Form D · Jan 18, 2013 ↗Ofir Paz — PartnerFacts page ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Nov 2, 2012 ↗ (Nov 2, 2012)
Form D · Jan 18, 2013 ↗ (Jan 18, 2013)
Ofir Paz — PartnerFacts page ↗
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Apr 18, 2012 – Oct 1, 2012

Asher Holzer's role changed at InspireMD, Inc.: executive officer, director → director

The Apr 18, 2012 filing lists Asher Holzer as executive officer, director; the Oct 1, 2012 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Form D · Apr 18, 2012 ↗Form D · Oct 1, 2012 ↗Asher Holzer — PartnerFacts page ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Apr 18, 2012 ↗ (Apr 18, 2012)
Form D · Oct 1, 2012 ↗ (Oct 1, 2012)
Asher Holzer — PartnerFacts page ↗
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Dec 12, 2017 – May 30, 2023

Thomas J. Kester is written 2 different ways on the filings

listed as "Thomas Kester" on the Dec 12, 2017 filing, and "Thomas J. Kester" on 2 filings (from May 30, 2023).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Dec 12, 2017 ↗Form D · May 30, 2023 ↗Thomas J. Kester — PartnerFacts page ↗

Sources

Note · Jan 18, 2013 – Mar 28, 2016

Alan Milinazzo is written 2 different ways on the filings

listed as "Alan W. Milinazzo" on the Jan 18, 2013 filing, and "Alan Milinazzo" on the Mar 28, 2016 filing.

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Jan 18, 2013 ↗Form D · Mar 28, 2016 ↗Alan Milinazzo — PartnerFacts page ↗

Sources

Note · Aug 26, 2011 – Apr 18, 2012

Sol J Barer is written 2 different ways on the filings

listed as "Sol J Barer" on 10 filings (from Aug 26, 2011), and "Sol Barer" on 3 filings (from Apr 18, 2012).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Aug 26, 2011 ↗Form D · Apr 18, 2012 ↗Sol J Barer — PartnerFacts page ↗

Sources

Note · Apr 14, 2011 – May 30, 2023

Industry group changed between filings — InspireMD, Inc.

"Other" (Apr 14, 2011 to Apr 18, 2012); then "Biotechnology" (Oct 1, 2012 to Dec 12, 2017); then "Other Health Care" (May 30, 2023 to Aug 4, 2025).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Apr 14, 2011 ↗Form D · Oct 1, 2012 ↗Form D · May 30, 2023 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Apr 14, 2011 ↗ (Apr 14, 2011)
Form D · Oct 1, 2012 ↗ (Oct 1, 2012)
Form D · May 30, 2023 ↗ (May 30, 2023)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · May 30, 2023 – Aug 4, 2025

Address moved from Tel Aviv, Israel (as filed: L3) to Miami, FL — InspireMD, Inc.

The people listed on the May 30, 2023 filing give Tel Aviv, Israel (as filed: L3); on the Aug 4, 2025 filing they give Miami, FL.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · May 30, 2023 ↗Form D · Aug 4, 2025 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · May 30, 2023 ↗ (May 30, 2023)
Form D · Aug 4, 2025 ↗ (Aug 4, 2025)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Jun 16, 2016 – Dec 12, 2017

Address moved from Boston, MA to Tel Aviv, Israel (as filed: L3) — InspireMD, Inc.

The people listed on the Jun 16, 2016 filing give Boston, MA; on the Dec 12, 2017 filing they give Tel Aviv, Israel (as filed: L3).

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jun 16, 2016 ↗Form D · Dec 12, 2017 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Jun 16, 2016 ↗ (Jun 16, 2016)
Form D · Dec 12, 2017 ↗ (Dec 12, 2017)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Jan 18, 2013 – Mar 28, 2016

Address moved from Tel Aviv, Israel (as filed: L3) to Boston, MA — InspireMD, Inc.

The people listed on the Jan 18, 2013 filing give Tel Aviv, Israel (as filed: L3); on the Mar 28, 2016 filing they give Boston, MA.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Form D · Jan 18, 2013 ↗Form D · Mar 28, 2016 ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

Form D · Jan 18, 2013 ↗ (Jan 18, 2013)
Form D · Mar 28, 2016 ↗ (Mar 28, 2016)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

Note · Apr 14, 2011 – Aug 4, 2025

Issuer used a different name before — InspireMD, Inc.

SEC records list prior names for this filer: Saguaro Resources, Inc.. The current name on file is "InspireMD, Inc.".

What this means A name change is normal, but your documents may show the old name. Match the CIK, not just the name.

EDGAR filer page ↗InspireMD, Inc. — PartnerFacts page ↗

Sources

EDGAR filer page ↗ (Aug 4, 2025)
InspireMD, Inc. — PartnerFacts page ↗ (Aug 4, 2025)

What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

4 of 19 offerings report sales commissions totalling $7,478,010; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)

Offering (latest filing)	Sales commissions	Finder's fees	To insiders	Paid to sell it	Source
Aug 4, 2025 D File 021-553632	$2,388,900 (est.)	$0	$0	BofA Securities, Inc. BrokerCheck CRD 000283942 ↗	EDGAR ↗
May 30, 2023 D File 021-482816	$4,191,600 (est.)	$0	$0	LifeSci Capital LLC BrokerCheck CRD 168404 ↗ A.G.P./Alliance Global Partners BrokerCheck CRD 8361 ↗ Piper Sandler & Co. BrokerCheck CRD 665 ↗	EDGAR ↗
Dec 12, 2017 D File 021-300556	$0	$0	$0	None listed on this filing	EDGAR ↗
Jun 16, 2016 D File 021-265182	$0	$0	$0	None listed on this filing	EDGAR ↗
Mar 28, 2016 D File 021-260088	$48,760	$0	$0	Dawson James Securities, Inc. BrokerCheck CRD 130645 ↗	EDGAR ↗
Jan 18, 2013 D File 021-190507	$0	$0	$0	None listed on this filing	EDGAR ↗
Nov 2, 2012 D File 021-186426	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 18, 2012 D File 021-185798	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 1, 2012 D File 021-184854	$0	$0	$0	None listed on this filing	EDGAR ↗
Oct 1, 2012 D File 021-184855	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 18, 2012 D File 021-176894	$848,750	$0	$0	Palladium Capital Advisors, LLC BrokerCheck CRD 129400 ↗ via Palladium Capital Advisors, LLC (CRD 129400 ↗) OPPENHEIMER & CO. INC. BrokerCheck CRD 249 ↗ via OPPENHEIMER & CO. INC. (CRD 249 ↗) JMP SECURITIES LLC BrokerCheck CRD 22208 ↗ via JMP SECURITIES LLC (CRD 22208 ↗)	EDGAR ↗
Aug 26, 2011 D File 021-165032	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 26, 2011 D File 021-165033	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 26, 2011 D File 021-165035	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 26, 2011 D File 021-165036	$0	$0	$0	None listed on this filing	EDGAR ↗
Aug 26, 2011 D File 021-165038	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 27, 2011 D File 021-158934	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 14, 2011 D File 021-158404	$0	$0	$0	None listed on this filing	EDGAR ↗
Apr 14, 2011 D File 021-158410	$0	$0	$0	None listed on this filing	EDGAR ↗

How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Property records 0 documents · 0 ownership records · last checked Oct 24, 2026, 9:34 AM ET · NYC and Cook County lookup still to run

0 recorded documents and 0 ownership records matched to InspireMD, Inc. in the sources searched.

Not found in sources searched as of Oct 24, 2026, 9:34 AM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Harris County TX (HCAD ownership rolls 2005–2026) — 1,032,426 records, loaded Oct 24, 2026, 8:00 AM ET; Dallas County TX (DCAD ownership rolls 2021–2027) — 285,535 records, loaded Oct 24, 2026, 8:20 AM ET; Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll) — 514,336 records, loaded Oct 24, 2026, 8:25 AM ET; King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published) — 538,619 records, loaded Oct 24, 2026, 8:27 AM ET; Cook County IL (Assessor sale records 1982–2026 + ownership rolls 1999–2026) — 1,263,035 records, loaded Oct 24, 2026, 9:34 AM ET. Still to be looked up for this issuer: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.

Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Harris County TX (ownership only, no deed, mortgage or sale records; HCAD ownership rolls 2005–2026); Dallas County TX (ownership only, no deed, mortgage or sale records; DCAD ownership rolls 2021–2027); Hillsborough County FL (FL DOR 2026 ownership roll + Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026), Miami-Dade County FL (FL DOR 2026 ownership roll), Broward County FL (FL DOR 2026 ownership roll), Palm Beach County FL (FL DOR 2026 ownership roll); King County WA (Assessor sale records 0000-00-00–2026-10-14; no owner-of-record names published); Cook County IL (Assessor sale records 1982–2026 + ownership rolls 1999–2026); also looked up per issuer when its page is viewed. Recorder indexes (party names on deeds, mortgages and liens) in TX, AZ, NV, CA and WA counties and outside the Clerk index in FL, mortgages and liens outside NYC and Hillsborough County, lis pendens and foreclosure notices everywhere, Los Angeles County CA, Clark County NV, New York City bulk pass (not finished; per-issuer lookups only so far), Maricopa County AZ (loader ready; commercial-purpose statement not yet filed), Salt Lake County UT, and all other counties are not covered — not searched. Last refresh by source: NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) Oct 24, 2026, 9:34 AM ET; Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 9:34 AM ET; Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp) Oct 24, 2026, 8:30 AM ET; King County WA Assessor Real Property Sales extract (EXTR_RPSale.csv) Oct 24, 2026, 8:27 AM ET; Florida DOR NAL roll (Palm Beach 60) Oct 24, 2026, 8:25 AM ET; Florida DOR NAL roll (Broward 16) Oct 24, 2026, 8:24 AM ET; Florida DOR NAL roll (Dade 23) Oct 24, 2026, 8:23 AM ET; Florida DOR NAL roll (Hillsborough 39) Oct 24, 2026, 8:21 AM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 24, 2026, 8:20 AM ET; Harris County Appraisal District real_acct.txt Oct 24, 2026, 8:00 AM ET; Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET. NYC and Cook County are also looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 3:30 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.

Offerings (SEC Form D)

Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.

Offerings at a glance — 19 offerings, 19 filings (one row per SEC file number)

File no.	Original Form D	Latest filing	Offered (latest)	Sold (latest)	Industry (latest)
021-553632	Aug 4, 2025 EDGAR ↗	Aug 4, 2025 D EDGAR ↗	$40,064,989	$40,064,989	Other Health Care
021-482816	May 30, 2023 EDGAR ↗	May 30, 2023 D EDGAR ↗	$42,168,087	$42,168,087	Other Health Care
021-300556	Dec 12, 2017 EDGAR ↗	Dec 12, 2017 D EDGAR ↗	$750,000	$750,000	Biotechnology
021-265182	Jun 16, 2016 EDGAR ↗	Jun 16, 2016 D EDGAR ↗	$182,399	$182,399	Biotechnology
021-260088	Mar 28, 2016 EDGAR ↗	Mar 28, 2016 D EDGAR ↗	$609,500	$609,500	Biotechnology
021-190507	Jan 18, 2013 EDGAR ↗	Jan 18, 2013 D EDGAR ↗	$3,089,945	$3,089,945	Biotechnology
021-186426	Nov 2, 2012 EDGAR ↗	Nov 2, 2012 D EDGAR ↗	$1,763,000	$1,763,000	Biotechnology
021-185798	Oct 18, 2012 EDGAR ↗	Oct 18, 2012 D EDGAR ↗	$450,158	$450,158	Biotechnology
021-184855	Oct 1, 2012 EDGAR ↗	Oct 1, 2012 D EDGAR ↗	$408,606	$408,606	Biotechnology
021-184854	Oct 1, 2012 EDGAR ↗	Oct 1, 2012 D EDGAR ↗	Indefinite	$0	Biotechnology
021-176894	Apr 18, 2012 EDGAR ↗	Apr 18, 2012 D EDGAR ↗	$11,000,000	$11,000,000	Other
021-165038	Aug 26, 2011 EDGAR ↗	Aug 26, 2011 D EDGAR ↗	$67,000	$67,000	Other
021-165036	Aug 26, 2011 EDGAR ↗	Aug 26, 2011 D EDGAR ↗	$1,500,000	$1,500,000	Other
021-165035	Aug 26, 2011 EDGAR ↗	Aug 26, 2011 D EDGAR ↗	$30,000	$30,000	Other
021-165033	Aug 26, 2011 EDGAR ↗	Aug 26, 2011 D EDGAR ↗	$4,000	$4,000	Other
021-165032	Aug 26, 2011 EDGAR ↗	Aug 26, 2011 D EDGAR ↗	$212,000	$212,000	Other
021-158934	Apr 27, 2011 EDGAR ↗	Apr 27, 2011 D EDGAR ↗	$10,000,000	$425,000	Other
021-158410	Apr 14, 2011 EDGAR ↗	Apr 14, 2011 D EDGAR ↗	$6,527,998	$6,527,998	Other
021-158404	Apr 14, 2011 EDGAR ↗	Apr 14, 2011 D EDGAR ↗	$8,041,000	$8,041,000	Other

Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.

Aug 4, 2025 D Other Health Care — $40,064,989 sold of $40,064,989 · 18 investors EDGAR ↗

Filing	Form D filed Aug 4, 2025 SEC file no. 021-553632 · accession 0001641172-25-022037
Raise progress	$40,064,989 sold of $40,064,989 offered (100%) · $0 remaining · first sale Jul 30, 2025
Filing timing	Date of first sale: Jul 30, 2025 · Form D filed: Aug 4, 2025 (5 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	452 days (1.2 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	18 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Shares of Common Stock & Warrants, including underlying common stock
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other Health Care
Who is paid to sell it	BofA Securities, Inc. — FINRA BrokerCheck CRD 000283942 ↗ Solicits in: All States
Money to insiders	Sales commissions: $2,388,900 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Marvin Slosman, President and CEO (Aug 4, 2025) Signed by an authorized representative.
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $40,064,989. Typical range: $829,831–$9,999,998. Investors: 18. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

May 30, 2023 D Other Health Care — $42,168,087 sold of $42,168,087 · 18 investors EDGAR ↗

Filing	Form D filed May 30, 2023 SEC file no. 021-482816 · accession 0001567619-23-006233
Raise progress	$42,168,087 sold of $42,168,087 offered (100%) · $0 remaining · first sale May 12, 2023 Issuer's note: Does not include cash amount if warrants exercised in full
Filing timing	Date of first sale: May 12, 2023 · Form D filed: May 30, 2023 (18 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	1,262 days (3.5 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	18 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Shares of Common Stock, and Common Stock Purchase Warrants (Series H, I, J, K Warrants) to purchase common stock, and underlying shares of common stock upon exercise of warrants.
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other Health Care
Who is paid to sell it	LifeSci Capital LLC — FINRA BrokerCheck CRD 168404 ↗ Solicits in: All States A.G.P./Alliance Global Partners — FINRA BrokerCheck CRD 8361 ↗ Solicits in: All States Piper Sandler & Co. — FINRA BrokerCheck CRD 665 ↗ Solicits in: All States
Money to insiders	Sales commissions: $4,191,600 (est.) · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Marvin Slosman, President and CEO (May 24, 2023)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $42,168,087. Typical range: $829,831–$9,999,998. Investors: 18. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Dec 12, 2017 D Biotechnology — $750,000 sold of $750,000 · 1 investors EDGAR ↗

Filing	Form D filed Dec 12, 2017 SEC file no. 021-300556 · accession 0001493152-17-014514
Raise progress	$750,000 sold of $750,000 offered (100%) · $0 remaining · first sale Dec 1, 2017
Filing timing	Date of first sale: Dec 1, 2017 · Form D filed: Dec 12, 2017 (11 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	3,250 days (8.9 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$750,000
Securities offered	Equity; Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Dec 12, 2017)
Market context	Minimum investment: $750,000. Typical range for similar offerings: $10,000–$50,000. Offering size: $750,000. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Jun 16, 2016 D Biotechnology — $182,399 sold of $182,399 · 1 investors EDGAR ↗

Filing	Form D filed Jun 16, 2016 SEC file no. 021-265182 · accession 0001615774-16-005941
Raise progress	$182,399 sold of $182,399 offered (100%) · $0 remaining · first sale Jun 13, 2016 Issuer's note: Total Offering Amount is the amount Issuer may receive upon exercise of the warrant. The warrant may also be exercised through partial and/or cashless exercise.
Filing timing	Date of first sale: Jun 13, 2016 · Form D filed: Jun 16, 2016 (3 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	3,786 days (10.4 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire; Security to be acquired upon exercise; Other: Warrant to purchase Common Stock.
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Jun 16, 2016)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $182,399. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Mar 28, 2016 D Biotechnology — $609,500 sold of $609,500 · 4 investors EDGAR ↗

Filing	Form D filed Mar 28, 2016 SEC file no. 021-260088 · accession 0001615774-16-004633
Raise progress	$609,500 sold of $609,500 offered (100%) · $0 remaining · first sale Mar 21, 2016
Filing timing	Date of first sale: Mar 21, 2016 · Form D filed: Mar 28, 2016 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	3,870 days (10.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	4 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	Dawson James Securities, Inc. — FINRA BrokerCheck CRD 130645 ↗ Solicits in: CA, MA, NJ, SC
Money to insiders	Sales commissions: $48,760 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Mar 27, 2016)
Market context	Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $609,500. Typical range: $2,000,000–$19,999,994. Investors: 4. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Jan 18, 2013 D Biotechnology — $3,089,945 sold of $3,089,945 · 1 investors EDGAR ↗

Filing	Form D filed Jan 18, 2013 SEC file no. 021-190507 · accession 0001433607-13-000001
Raise progress	$3,089,945 sold of $3,089,945 offered (100%) · $0 remaining · first sale Jan 3, 2013 Issuer's note: Grant of nonqualified stock option to purchase 525,927 shares of the Company?s common stock, incentive stock option to purchase 74,073 shares of common stock and 400,000 shares of restricted stock to the Company's CEO under his employment agreement.
Filing timing	Date of first sale: Jan 3, 2013 · Form D filed: Jan 18, 2013 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,043 days (13.8 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Jan 18, 2013)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Nov 2, 2012 D Biotechnology — $1,763,000 sold of $1,763,000 · 1 investors EDGAR ↗

Filing	Form D filed Nov 2, 2012 SEC file no. 021-186426 · accession 0001433607-12-000005
Raise progress	$1,763,000 sold of $1,763,000 offered (100%) · $0 remaining · first sale Oct 24, 2012 Issuer's note: Shares granted to licensor in consideration of amendment to license agreement.
Filing timing	Date of first sale: Oct 24, 2012 · Form D filed: Nov 2, 2012 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,114 days (14.0 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Nov 2, 2012)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Oct 18, 2012 D Biotechnology — $450,158 sold of $450,158 · 1 investors EDGAR ↗

Filing	Form D filed Oct 18, 2012 SEC file no. 021-185798 · accession 0001433607-12-000004
Raise progress	$450,158 sold of $450,158 offered (100%) · $0 remaining · first sale Sep 27, 2012 Issuer's note: Exercise of warrants to purchase shares of common stock.
Filing timing	Date of first sale: Sep 27, 2012 · Form D filed: Oct 18, 2012 (21 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,141 days (14.1 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Security to be acquired upon exercise
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Oct 18, 2012)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Oct 1, 2012 D Biotechnology — $408,606 sold of $408,606 · 1 investors EDGAR ↗

Filing	Form D filed Oct 1, 2012 SEC file no. 021-184855 · accession 0001433607-12-000003
Raise progress	$408,606 sold of $408,606 offered (100%) · $0 remaining · first sale Sep 14, 2012 Issuer's note: Exercise of warrants to purchase shares of common stock.
Filing timing	Date of first sale: Sep 14, 2012 · Form D filed: Oct 1, 2012 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,154 days (14.1 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Security to be acquired upon exercise
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Oct 1, 2012)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Oct 1, 2012 D Biotechnology — $0 sold of Indefinite · 1 investors EDGAR ↗

Filing	Form D filed Oct 1, 2012 SEC file no. 021-184854 · accession 0001433607-12-000002
Raise progress	$0 sold of Indefinite offered · Indefinite remaining · first sale Aug 1, 2012 Issuer's note: Options granted to consultant in consideration of services to be rendered.
Filing timing	Date of first sale: Aug 1, 2012 · Form D filed: Oct 1, 2012 (61 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,198 days (14.2 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Biotechnology
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Oct 1, 2012)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Apr 18, 2012 D Other — $11,000,000 sold of $11,000,000 · 6 investors EDGAR ↗

Filing	Form D filed Apr 18, 2012 SEC file no. 021-176894 · accession 0001544732-12-000004
Raise progress	$11,000,000 sold of $11,000,000 offered (100%) · $0 remaining · first sale Apr 5, 2012 Issuer's note: The company issued convertible promissory notes in the aggregate principal amount of $11,702,128 with an original issue discount of 6%, resulting in aggregate gross proceeds to the company of $11,000,000.
Filing timing	Date of first sale: Apr 5, 2012 · Form D filed: Apr 18, 2012 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,316 days (14.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	6 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Debt; Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	Palladium Capital Advisors, LLC — FINRA BrokerCheck CRD 129400 ↗ · associated broker-dealer: Palladium Capital Advisors, LLC (CRD 129400 ↗) Solicits in: NY OPPENHEIMER & CO. INC. — FINRA BrokerCheck CRD 249 ↗ · associated broker-dealer: OPPENHEIMER & CO. INC. (CRD 249 ↗) Solicits in: CA JMP SECURITIES LLC — FINRA BrokerCheck CRD 22208 ↗ · associated broker-dealer: JMP SECURITIES LLC (CRD 22208 ↗) Solicits in: CA
Money to insiders	Sales commissions: $848,750 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Apr 18, 2012)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Aug 26, 2011 D Other — $67,000 sold of $67,000 · 1 investors EDGAR ↗

Filing	Form D filed Aug 26, 2011 SEC file no. 021-165038 · accession 0001433607-11-000010
Raise progress	$67,000 sold of $67,000 offered (100%) · $0 remaining · first sale Apr 18, 2011
Filing timing	Date of first sale: Apr 18, 2011 · Form D filed: Aug 26, 2011 (130 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,669 days (15.5 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Aug 26, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Aug 26, 2011 D Other — $1,500,000 sold of $1,500,000 · 3 investors EDGAR ↗

Filing	Form D filed Aug 26, 2011 SEC file no. 021-165036 · accession 0001433607-11-000009
Raise progress	$1,500,000 sold of $1,500,000 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Aug 26, 2011 (148 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	3 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Aug 26, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Aug 26, 2011 D Other — $30,000 sold of $30,000 · 1 investors EDGAR ↗

Filing	Form D filed Aug 26, 2011 SEC file no. 021-165035 · accession 0001433607-11-000008
Raise progress	$30,000 sold of $30,000 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Aug 26, 2011 (148 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Aug 26, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Aug 26, 2011 D Other — $4,000 sold of $4,000 · 1 investors EDGAR ↗

Filing	Form D filed Aug 26, 2011 SEC file no. 021-165033 · accession 0001433607-11-000007
Raise progress	$4,000 sold of $4,000 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Aug 26, 2011 (148 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Aug 26, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Aug 26, 2011 D Other — $212,000 sold of $212,000 · 1 investors EDGAR ↗

Filing	Form D filed Aug 26, 2011 SEC file no. 021-165032 · accession 0001433607-11-000006
Raise progress	$212,000 sold of $212,000 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Aug 26, 2011 (148 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	1 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Aug 26, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Apr 27, 2011 D Other — $425,000 sold of $10,000,000 · 2 investors EDGAR ↗

Filing	Form D filed Apr 27, 2011 SEC file no. 021-158934 · accession 0001433607-11-000005
Raise progress	$425,000 sold of $10,000,000 offered (4%) · $9,575,000 remaining · first sale Apr 18, 2011
Filing timing	Date of first sale: Apr 18, 2011 · Form D filed: Apr 27, 2011 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,669 days (15.5 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	2 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Apr 27, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Apr 14, 2011 D Other — $6,527,998 sold of $6,527,998 · 16 investors EDGAR ↗

Filing	Form D filed Apr 14, 2011 SEC file no. 021-158410 · accession 0001433607-11-000004
Raise progress	$6,527,998 sold of $6,527,998 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Apr 14, 2011 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	16 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity · business combination transaction
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Apr 14, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

Apr 14, 2011 D Other — $8,041,000 sold of $8,041,000 · 24 investors EDGAR ↗

Filing	Form D filed Apr 14, 2011 SEC file no. 021-158404 · accession 0001433607-11-000003
Raise progress	$8,041,000 sold of $8,041,000 offered (100%) · $0 remaining · first sale Mar 31, 2011
Filing timing	Date of first sale: Mar 31, 2011 · Form D filed: Apr 14, 2011 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn.
Time since first sale	5,687 days (15.6 years)
Annual amendments	Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn.
Investors	24 total · issuer reported no non-accredited investors
Exemption claimed	Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c))
Minimum investment accepted	$0 as filed (no minimum reported)
Securities offered	Equity; Option, warrant or other right to acquire
Entity details	Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5).
Industry	Other
Who is paid to sell it	No sales compensation recipients listed on this filing.
Money to insiders	Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0
Signed by	Craig Shore, Chief Financial Officer (Apr 14, 2011)
Market context	Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings.
Source	This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET

All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Aug 4, 2025. Industry as reported, by offering: Previous offerings: Other (2011–2012), Biotechnology (2012–2017). Latest offering: Other Health Care (2023–2025; most recent Aug 4, 2025).

Key people 26

Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.

Name	Relationship	Address state	On filings (first → last)	Also listed on
AT Andrea Tommasoli	Executive Officer Issuer's note: Chief Operating Officer	Israel (as filed: L3)	May 30, 2023 → Aug 4, 2025 on 2 of 19 filings listed on the latest filing	—
GD Gary Roubin, M.D.	Director	Israel (as filed: L3)	May 30, 2023 → Aug 4, 2025 on 2 of 19 filings listed on the latest filing	—
KA Kathryn Arnold	Director	Israel (as filed: L3)	May 30, 2023 → Aug 4, 2025 on 2 of 19 filings listed on the latest filing	1 other issuer
MS Marvin Slosman	Executive Officer, Director Issuer's note: President and Chief Executive Officer	Israel (as filed: L3)	May 30, 2023 → Aug 4, 2025 on 2 of 19 filings listed on the latest filing	—
MB Michael Berman	Director Issuer's note: Director	MA	Mar 28, 2016 → Aug 4, 2025 on 5 of 19 filings listed on the latest filing	1 other issuer
ML Mike Lawless	Executive Officer Issuer's note: Chief Financial Officer	FL	Aug 4, 2025 on 1 of 19 filings listed on the latest filing	—
PV Patrick Verta	Executive Officer	FL	Aug 4, 2025 on 1 of 19 filings listed on the latest filing	—
PS Paul Stuka	Director Issuer's note: Director	MA	Aug 26, 2011 → Aug 4, 2025 on 14 of 19 filings listed on the latest filing	—
PL Pete Ligotti	Executive Officer	FL	Aug 4, 2025 on 1 of 19 filings listed on the latest filing	—
RC Raymond Cohen	Director	FL	Aug 4, 2025 on 1 of 19 filings listed on the latest filing	—
SW Scott R. Ward	Director	FL	Aug 4, 2025 on 1 of 19 filings listed on the latest filing	—
SG Shane Gleason	Executive Officer Issuer's note: General Manager of North America & VP of Global Marketing	Israel (as filed: L3)	May 30, 2023 → Aug 4, 2025 on 2 of 19 filings listed on the latest filing	—
TK Thomas J. Kester also filed as Thomas Kester	Director Issuer's note: Director	Israel (as filed: L3)	Dec 12, 2017 → Aug 4, 2025 on 3 of 19 filings listed on the latest filing	—
CS Craig Shore	Executive Officer Issuer's note: Chief Financial Officer, Secretary and Treasurer	MA	Apr 14, 2011 → May 30, 2023 on 18 of 19 filings not listed on the latest filing (Aug 4, 2025)	—
CR Campbell Rogers	Director Issuer's note: Director	MA	Mar 28, 2016 → Dec 12, 2017 on 3 of 19 filings not listed on the latest filing (Aug 4, 2025)	—
JB James Barry	Director, Executive Officer Issuer's note: President, Chief Executive Officer and Director of the Issuer	MA	Apr 18, 2012 → Dec 12, 2017 on 9 of 19 filings not listed on the latest filing (Aug 4, 2025)	2 other issuers
IB Isaac Blech	Director	MA	Mar 28, 2016 → Jun 16, 2016 on 2 of 19 filings not listed on the latest filing (Aug 4, 2025)	19 other issuers
PS Paul Stuke	Director	MA	Mar 28, 2016 → Jun 16, 2016 on 2 of 19 filings not listed on the latest filing (Aug 4, 2025)	—
SB Sol Barer also filed as Sol J Barer; Sol J. Barer	Director	NJ	Aug 26, 2011 → Jun 16, 2016 on 13 of 19 filings not listed on the latest filing (Aug 4, 2025)	8 other issuers
AM Alan Milinazzo also filed as Alan W. Milinazzo	Executive Officer, Director	MA	Jan 18, 2013 → Mar 28, 2016 on 2 of 19 filings not listed on the latest filing (Aug 4, 2025)	2 other issuers
JL James Loughlin	Director	MA	Oct 1, 2012 → Mar 28, 2016 on 6 of 19 filings not listed on the latest filing (Aug 4, 2025)	1 other issuer
AH Asher Holzer	Executive Officer, Director	Israel (as filed: L3)	Apr 14, 2011 → Jan 18, 2013 on 14 of 19 filings not listed on the latest filing (Aug 4, 2025)	1 other issuer
EB Eli Bar	Executive Officer	Israel (as filed: L3)	Oct 1, 2012 → Jan 18, 2013 on 5 of 19 filings not listed on the latest filing (Aug 4, 2025)	2 other issuers
EW Eyal Weinstein	Director	Israel (as filed: L3)	Aug 26, 2011 → Jan 18, 2013 on 11 of 19 filings not listed on the latest filing (Aug 4, 2025)	1 other issuer
OP Ofir Paz	Executive Officer, Director	Israel (as filed: L3)	Apr 14, 2011 → Jan 18, 2013 on 14 of 19 filings not listed on the latest filing (Aug 4, 2025)	1 other issuer
RR Robert Ratini	Executive Officer	Israel (as filed: L3)	Oct 1, 2012 → Jan 18, 2013 on 5 of 19 filings not listed on the latest filing (Aug 4, 2025)	—

Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (Gary J. Roubin, M.D.; Kathryn J. Arnold; Paul J Stuka; Paul J. Stuka; Raymond J. Cohen; Craig W. Shore; James J. Barry; James J. Loughlin; Asher J. Holzer; Eli W. Bar; Eyal J Weinstein; Eyal J. Weinstein; Ofir J. Paz; Robert W. Ratini) — the filing on EDGAR is the source.

Connections

Other issuers listing the same people:

WaveGuide Corp — Isaac Blech · latest filing Jul 30, 2026
Nacuity Pharmaceuticals, Inc. — Isaac Blech · latest filing Dec 30, 2025
Avalo Therapeutics, Inc. — Sol J Barer · latest filing Apr 9, 2024
Avalo Therapeutics, Inc. — Isaac Blech · latest filing Apr 9, 2024
Centrexion Therapeutics Corp — Sol J Barer · latest filing Jan 8, 2024
Centrexion Therapeutics Corp — Isaac Blech · latest filing Jan 8, 2024
AMICUS THERAPEUTICS, INC. — Sol J Barer · latest filing Oct 16, 2023
Elucida Oncology, Inc. — Isaac Blech · latest filing Aug 3, 2023
Aridis Pharmaceuticals, Inc. — Isaac Blech · latest filing Dec 20, 2022
Elicio Therapeutics, Inc. — Isaac Blech · latest filing Nov 2, 2022
Alveo Technologies Inc. — Isaac Blech · latest filing Mar 29, 2021
EyePoint Pharmaceuticals, Inc. — James Barry · latest filing Jan 6, 2021
Sapience Therapeutics, Inc. — Isaac Blech · latest filing Jul 13, 2020
Diffusion Pharmaceuticals Inc. — Sol J Barer · latest filing May 27, 2020
Diffusion Pharmaceuticals Inc. — Isaac Blech · latest filing May 27, 2020
Adhera Therapeutics, Inc. — Isaac Blech · latest filing Feb 19, 2020
Valfix Medical Inc. — Eli Bar · latest filing Oct 10, 2019
X-Vax Technology, Inc. — Isaac Blech · latest filing Jul 18, 2019
Arsenal Medical, Inc. — James Barry · latest filing Jun 7, 2019
Oceanside Golf & Country Club, Inc. — Kathryn Arnold · latest filing Sep 24, 2018
X4 Pharmaceuticals, Inc. — Isaac Blech · latest filing Sep 21, 2018
Tri-Medics, LLC — Alan Milinazzo · latest filing Jul 2, 2018
Aevi Genomic Medicine, Inc. — Sol J Barer · latest filing Oct 19, 2017
Aevi Genomic Medicine, Inc. — Isaac Blech · latest filing Oct 19, 2017
root9B Technologies, Inc. — Isaac Blech · latest filing Sep 26, 2016
Regenovation, Inc. — Isaac Blech · latest filing Sep 8, 2016
CONTRAFECT Corp — Sol J Barer · latest filing Jun 25, 2015
CONTRAFECT Corp — Isaac Blech · latest filing Jun 25, 2015
Edge Therapeutics, Inc. — Sol J Barer · latest filing Apr 9, 2015
Edge Therapeutics, Inc. — Isaac Blech · latest filing Apr 9, 2015
Edge Therapeutics, Inc. — James Loughlin · latest filing Apr 9, 2015
LOTSA HELPING HANDS INC — Michael Berman · latest filing Jun 6, 2014
MIG IRC, LLC — Sol J Barer · latest filing Mar 31, 2014
SpendSmart Payments Co — Isaac Blech · latest filing Mar 18, 2014
Flexion Therapeutics Inc — Alan Milinazzo · latest filing Dec 14, 2012
InspireMD Ltd. — Asher Holzer · latest filing Aug 6, 2010
InspireMD Ltd. — Ofir Paz · latest filing Aug 6, 2010
InspireMD Ltd. — Eyal Weinstein · latest filing Aug 6, 2010
InspireMD Ltd. — Eli Bar · latest filing Aug 6, 2010

Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Adviser registration (Form ADV)

Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched InspireMD, Inc..

Meta advertising

No Meta Pixel ids or Facebook / Instagram page links on file for InspireMD, Inc. as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.

Public profiles

Public profiles official links and public statements, each with its source and date

No website or social profile named in InspireMD, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #64,011 of 374,652 in line (1,386 issuers searched so far).

Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.

Entity standing: not checked (no official programmatic source for FL yet).

Export this report as PDF (all source links + data timestamp) · Premium

Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".

Corrections log

No corrections have been requested for this page.

Filing-to-filing changes are in Amendment history above.

Facts from public records only, each linked to its source. No ratings, no opinions. Request a correction · Claim this profile · Facts policy

Email me the full report

The complete public-record profile for InspireMD, Inc., plus the weekly new-filings list.

What do you want to do?

Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.

Request a correction

Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).

Sponsor response

Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.

Claim this profile (sponsors)

Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Miami, FL). Each opens in a new tab; what you find there is not verified by PartnerFacts.

InspireMD, Inc.

The short version

Business registration (state registry / Secretary of State)

What the community is saying

Key records

1. Lawsuits

2. Regulatory actions

3. Bankruptcies

4. Differences between public sources

Bankruptcy case: Nathaniel Thomas and Verta Vanessa Thomas — filed Sep 25, 2012

9 Form Ds were filed more than 15 days after the first sale

No amendment in the last 12 months on an offering that may still be open — InspireMD, Inc. (latest filing Oct 1, 2012)

No amendment in the last 12 months on an offering that may still be open — InspireMD, Inc. (latest filing Apr 27, 2011)

James Barry's role changed at InspireMD, Inc.: director → executive officer, director

Ofir Paz's role changed at InspireMD, Inc.: executive officer, director → director

Asher Holzer's role changed at InspireMD, Inc.: executive officer, director → director

Thomas J. Kester is written 2 different ways on the filings

Alan Milinazzo is written 2 different ways on the filings

Sol J Barer is written 2 different ways on the filings

Industry group changed between filings — InspireMD, Inc.

Address moved from Tel Aviv, Israel (as filed: L3) to Miami, FL — InspireMD, Inc.

Address moved from Boston, MA to Tel Aviv, Israel (as filed: L3) — InspireMD, Inc.

Address moved from Tel Aviv, Israel (as filed: L3) to Boston, MA — InspireMD, Inc.

Issuer used a different name before — InspireMD, Inc.

5. Money to insiders

Offerings (SEC Form D)

Key people 26

Connections

Other offering types (Regulation A and Regulation Crowdfunding)

Adviser registration (Form ADV)

Meta advertising

Public profiles

Corrections log

Email me the full report

What do you want to do?

Request a correction

Sponsor response

Claim this profile (sponsors)

Look further

Social and web

Courts

Securities regulators

Business registries